Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 4Phase 4 2Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Pancreatic Fistula 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × pasireotide × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

NCT02775227 2020-08-24

HYPAR

Helsinki University Central Hospital

Phase 4 Active not recruiting
126 enrolled
Gastrointestinal

Pancreatic Fistula, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡